Johnson & Johnson has beaten expectations on earnings and revenue after announcing its results for second-quarter 2019.
The healthcare and beauty group increased its guidance for 2019, forecasting revenue of between US$80.8bn and $81.6bn, following a 12% increase in net earnings for Q2 to reach $5.6bn.
Sales were up on forecast figures, to reach $20.6bn but down 1% yearly due to currency fluctuations.
Its consumer division’s worldwide operational sales, which includes the brand Neutrogenea, Aveeno and OGX grew 2.3%.
"We delivered solid second-quarter underlying sales growth and strong earnings growth that enables us to make investments in innovation to accelerate performance in each of our businesses," said Alex Gorsky, chairman and CEO.
“Our pipelines continue to progress with the launch of new products and several regulatory submissions and approvals, which positions us well to deliver the next wave of transformational products and solutions.
“I am proud of our talented colleagues across Johnson & Johnson who continue to deliver significant healthcare advances to improve the lives of patients and consumers around the world."
